Development of Antibody-Based Therapeutics
Translational Considerations & Challenges
(Sprache: Englisch)
This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including the relationship between the 'unit dose' and 'unit effect' with respect to beneficial and deleterious effects.
Voraussichtlich lieferbar in 3 Tag(en)
versandkostenfrei
Buch (Kartoniert)
164.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Development of Antibody-Based Therapeutics “
This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including the relationship between the 'unit dose' and 'unit effect' with respect to beneficial and deleterious effects.
Klappentext zu „Development of Antibody-Based Therapeutics “
With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.
Inhaltsverzeichnis zu „Development of Antibody-Based Therapeutics “
1. Introduction.- 2. Translational Considerations and Challenges: An Overview.- 3. Considerations for Construct and Affinity Design Goals.- 4. Epitope Characterization and Isotype Selection.- 5. Biophysical Considerations for Development of Antibody-Based Therapeutics.- 6. Novel Technologies for Generation of Bispecific Constructs.- 7. Stimulus-Response Mechanisms: An Overview.- 8. Evaluation of Tumor Growth Inhibition in Preclinical Tumor Models -A Quantitative Approach.- 9. Application of Proof-of-Mechanism Biomarkers (POM) in Design and Development of Biologics Modalities.- 10. Antibody Drug Conjugates: Translational Considerations.- 11. Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs.- 12. Translational Biomarkers: Application in the Clinical Development of Combination Therapies.
Autoren-Porträt
Mohammad A. Tabrizi, Ph.D. is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies.Gadi G. Bornstein, Ph.D. has nearly twenty years of experience in Oncology R&D with an emphasis in preclinical antibody discovery and development. Dr. Bornstein currently leads and directs biologics discovery efforts at TESARO. He received his B.S. in biochemistry at the University of California, Davis and his doctoral degree in biochemistry at the University of Southern California Keck School of Medicine. Dr. Bornstein completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology.
Bibliographische Angaben
- 2019, 2. Aufl., VIII, 248 Seiten, 87 farbige Abbildungen, Maße: 16,1 x 23,7 cm, Kartoniert (TB), Englisch
- Herausgegeben: Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp
- Verlag: Springer, Berlin
- ISBN-10: 9811344329
- ISBN-13: 9789811344329
Sprache:
Englisch
Kommentar zu "Development of Antibody-Based Therapeutics"
Schreiben Sie einen Kommentar zu "Development of Antibody-Based Therapeutics".
Kommentar verfassen